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ABSTRACT
The specific 1,3 dipolar Hu ¨isgen cycloaddition
reaction known as ‘click-reaction’ between azide
and alkyne groups is employed for the synthesis
of peptide–oligonucleotide conjugates. The peptide
nucleic acids (PNA)/DNA and peptides may be
appended either by azide or alkyne groups.
The cycloaddition reaction between the azide and
alkyne appended substrates allows the synthesis of
the desired conjugates in high purity and yields
irrespective of the sequence and functional groups
on either of the two substrates. The versatile
approach could also be employed to generate the
conjugates of peptides with thioacetamido nucleic
acid (TANA) analog. The click reaction is catalyzed
by Cu (I) in either water or in organic medium.
In water, »3-fold excess of the peptide-alkyne/azide
drives the reaction to completion in 2h with no side
products.
INTRODUCTION
Uncharged, achiral peptide nucleic acids (PNAs) are
DNA mimics that show unprecedented aﬃnity towards
complementary RNA and DNA sequences(1,2). PNA and
other modiﬁed oligonucleotides (ONs) (3–7) are currently
being developed as DNA mimics to target disease-causing
mRNA (8,9), using the principle of antisense action. This
is gaining further importance because of corrective anti-
sense therapies that do not require activation of RNase H
enzyme or cleavage of the target mRNA (10). The success
or failure of any such candidate in antisense therapeutics
depends on a number of factors such as sequence-speciﬁc
recognition of target mRNA, intracellular stability, water
solubility (3) and cell penetration (11). Application of
PNA and analogous uncharged DNA mimics is stymied
by the fact that PNAs show very low cell penetration
for any observable antisense eﬀect (12). Several strategies
are being developed for the delivery of modiﬁed ONs
into cells (13,14). For uncharged ON mimics such as
PNAs, the best option seems to be the covalent conjuga-
tion of PNA oligomers with cell-penetrating peptides
(CPP) (15–17). Conjugation of peptides to DNA and
DNA analogs with sugar-phosphate backbone ONs is also
gaining importance for their biological applications
(13,14). The CPPs are mostly positively charged peptides
containing lysine (18) or arginine (19,20) or other peptides
having speciﬁc cell receptors (21). Several other uses of
peptide conjugation with ONs are known in the litera-
ture(13). The conjugation is achieved by tedious contin-
uous solid-phase synthesis of PNA and peptide (22–25).
The other methods for conjugation could be post-
synthetic via disulﬁde bridge (26,27) or more stable
thioether linkages (21) at either C- or N- terminus.
A recent review (13) not only summarizes the present
methods of synthesizing ON–peptide conjugates that are
common to ONs and their analogs but also points out
the need to develop straightforward methods to synthesize
such conjugates. The highly functionalized nature of these
biomolecules and their mimics such as PNA, render them
susceptible for side reactions during conjugation and yield
and purity of structurally deﬁned conjugated biomole-
cules is often low. The (4+2) Diels-Alder cycloaddition
approach was employed recently for the conjugation of
DNA and CPP (28). This involved the reaction between
diene and dienophile present on the respective biomole-
cules to get the conjugates. The maleimide dienophile used
in this reaction is susceptible for Michael addition reac-
tions with other nucleophilic centers on peptides or ONs
and may give rise to side reactions. The current literature
clearly indicates the need for a simple and straightforward
strategy for generating highly pure ON/PNA–peptide
conjugates in high yield (13).
Meanwhile, we ﬁnd that the applications of highly
selective orthogonal Cu (I) catalyzed Hu ¨ isgen 1, 3 dipolar
cycloadddition reaction, recognized as ‘click chemistry’
(29–32), are expanding the scope of synthesis of variety
of other bioconjugates such as DNA-glycoconjugates (33),
peptide–protein conjugates (34), carbohydrate–vaccine
conjugates (35) or protein modiﬁcation and protein
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energy organic azides and terminal alkynes can give rise to
unlimited array of inert triazole containing architectures
(Scheme 1). The reaction is highly predictable, fast and
resistant to side reactions. Addition of Cu(I) accelerates
the reaction (31,32). Some of these reactions could be
carried out in aqueous medium and can be employed post-
synthetically on puriﬁed units decorated with a variety of
functional groups, without additional functional group
protecting strategies. Recently, click reaction has also
found applications for the synthesis of circular DNA
(37,38), and DNA-template-directed ON strand ligation
(38). With this background we envisaged a very simple
possibility of synthesizing peptide–DNA/PNA conjugates
using click chemistry i.e. a speciﬁc cycloaddition reaction
between terminal azide and alkyne functionalities on
PNA/DNA or peptide as per the synthesis design. These
two functional groups are absent in the biomolecules
of current interest and no predictable side reaction can be
envisaged. This approach has not been previously applied
to the synthesis of such conjugates and has potential
to lead to a variety of CPP–DNA/PNA conjugates from
various combinations of azide and alkyne derivatized
peptides-ON substrates in aqueous solution without going
into the rigors of continuous synthesis. In this paper, we
report successful application of this proposal to generate
the CPP conjugates with DNA/PNA ONs and thioaceta-
mido nucleic acid (TANA, Figure 1) (39,40).
MATERIALS AND METHODS
N
a-Fmoc L-amino acids and resins for peptide and PNA
synthesis were obtained from Novabiochem(Fmoc,
9-ﬂuorenyl methoxy-carbonyl). The Fmoc amino
acid used were Fmoc -Lys(Boc)-OH, Fmoc-Arg(Mtr)-
OH and N
e-Fmoc-Aha-OH.(Mtr, 4-methoxy-2,3,
6-trimethylbenzenesulfonyl; Boc, tert-butoxycarbonyl;
Aha, 6-aminohexanoic acid (or e-aminocaproic acid).
6-aminohexanoic acid was obtained from Aldrich
chemicals and N-Fmoc protection was done using
standard procedure. The concentrations of DNA/PNAs
and their conjugates were determined spectrophotometri-
cally and the concentration of the peptides was assumed
approximately. Propynoic acid was procured from Trade
(TCI) Mark, Tokyo Kasei. N-Boc-(2S,4 S)-4-azidoproline
was synthesized according to the reported procedure (41).
The Boc and Fmoc protected PNA monomers were
obtained from Applied Biosystems, USA. TANA mono-
mers were synthesized in the laboratory following the
reported procedures (39). Propyne substituted 19-mer
DNA sequence was synthesized using the phosphorami-
dite approach and an Applied Biosystems 3900 DNA
synthesizer.
Reverse phase high-performance liquid chromatogra-
phy analyses were carried out on VARIAN Analytical
Semi-prep HPLC system consisting of Varian Pro-star 210
Binary solvent delivery system. Linear gradients of A:
0.1% TFA in water and B: 55/45: Acetonitrile/Water,
0.1% TFA (Linear gradient from A to B in 30min Flow-
1.5ml/min.). Rainin Dynamax UV D-II Absorbance
Detector Star Ver.5at detection wavelength 254nm
or 220nm was employed during the experimentation.
Chromatography Workstation Rheodyne 7725I with
manual injector and Lichrocart Lichrispher 100RP-
18250 4mm id. Particle size-5mm column were used.
Mass spectral analysis was performed on a Voyager-
De-STR (Applied Biosystems) MALDI-TOF. A nitrogen
laser (337nm) was used for desorption. The matrixes used
for analysis were CHCA (a-Cyano-4-hydroxycinnamic
Acid), THAP (20,4 0,and 60-trihydroxyacetophenone) and
HPA (3-hydroxypicolinic acid). Diammonium citrate was
usedasadditivewhenTHAPandHPAwereusedasmatrix.
Solid-phase synthesis of azide functionalized
PNA oligomers 2, 3and4
The azide functionalized PNA oligomers 2 and 3 were
synthesized on Rink-amide resin (100mg, loading
0.3mmol/g) following the standard procedures of solid-
phase peptide synthesis (42) (20min treatment with 20%
piperidine in N,N-dimethyl formamide and reaction with
3 equivalents of Fmoc-PNA monomer, HBTU, HOBt
and DIPEA for 6h, were used for the deprotection and
coupling steps, respectively). The last coupling reaction
was done with N-Boc-(2S,4S)-4-azidoproline. The pro-
gress of the coupling reaction was tested by Kaiser test at
each step. Cleavage and deprotection were eﬀected
by reaction with TFA/DCM/TIS (10:85:5) for 30min.
The resulting oligomer was precipitated by addition of
cold ether and puriﬁcation was done by gel ﬁltration
followed by RP–HPLC and characterized by MALDI-
TOF mass spectrometry (Table 1, entry 3, 6).
The azide functionalized mixed PNA oligomer 4 was
synthesized using side chain N-Cbz protected Boc-
L-Lysine functionalized MBHA resin (100mg, loading
0.2mmol/g) following the standard procedures of solid-
phase peptide synthesis (30min treatment with 50% TFA
in DCM and reaction with three equivalents of Boc-PNA
TANA backbone (t) DNA/RNA aeg PNA backbone
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Figure 1. DNA/RNA and PNA and TANA.
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Scheme 1. Huisgen [3+2] cycloaddition reaction between azide and
terminal alkyne groups to give inert triazoles.
e139 Nucleic Acids Research, 2007, Vol. 35, No. 21 PAGE2 OF 7monomer, HBTU, HOBt and DIPEA for 6h, were used
for the deprotection and coupling steps, respectively). The
last coupling reaction was done with N-Boc-(2S,4S)-
4-azidoproline. Cleavage and deprotection were carried
out by the reaction with TFA-TFMSA, thioanisole,
ethanedithiol for 2h. The resulting oligomer was pre-
cipitated by addition of cold ether and puriﬁcation was
done by gel ﬁltration followed by RP–HPLC and
characterized by MALDI-TOF mass spectrometry
(Table 1, entry 9).
Solid-phase synthesis of alkyne functionalized lysine
peptide HO-(Lys)6-alkyne 1
The alkyne functionalized lysine peptide was synthesized
on Rink-amide resin (100mg, loading 0.3mmol/g) follow-
ing the standard procedures of solid-phase peptide
synthesis (42) (20min treatment with 20% piperidine in
N,N-dimethyl formamide and the reaction with 3 eqiva-
lent of Fmoc-Lys(Boc)-OH, HBTU, HOBt and DIPEA
for 4h, were used for the deprotection and coupling steps,
respectively). The last coupling was done with propynoic
acid using HBTU, HOBt and DIPEA as the coupling
agent. The peptide was cleaved from the resin by
treatment with TFA/DCM/TIS (10:85:5) for 30min
and the deprotection of side chain was eﬀected by 50%
TFA-DCM (TIS used as scavenger) for 1h. The resulting
peptide was precipitated by addition of cold ether.
The product was puriﬁed by HPLC and characterized by
MALDI-TOF mass spectrometry (Table 1, entry 1).
Clickreaction onsolid phase: synthesis of
HO-(Lys)6-triazole-proline 5
Twenty milligrams of resin bound to protected (Lys)6-
alkyne 1, N-Boc-(2S,4S)-4-azidoproline (5mg) (37),
CuI(1mg), DIPEA(5ml) and DMF(0.3ml) were reacted
together in a reaction vessel for 8h (Scheme 2). The excess
Table 1. The RP-HPLC-tR and MALDI-TOF mass characterization and purity found by HPLC of the peptide, PNA and TANA sequences and
peptide–PNA and peptide–TANA conjugates
Compounds HPLC
a Purity (%) Mass
Calcd. Found
1 HO-(Lys)6-alkyne 1 9.7 91 839.08 837.8
2 HO-(Lys)6-triazole-Pro 5 9.59 90 995.23 996.5
3 HO-b-ala-TTTTTTTT-Pro-N3 2 12.6 99.1 2356.2 2356.6
4 HO-b-ala-TTTTTTTT-Pro-triazole(Lys)6-OH 6 12.29
b 100 3195.3 3195.35
b
5 Mixture of 2+6 when reaction 12.4 41
was still incomplete 12.1 50
6 HO-b-ala-tttttttt-Pro-N3 3 18.5 100 2605.3 2628(+Na
+)
7 HO-b-ala-tttttttt-Pro-triazole-(Lys)6 7 17.2 100 3444.9 3444.0
8 Mixture of 3+7 when reaction 18.3 48.7
was still incomplete 17.05 43.5
9 HO-Lys-TCACTAGATG- Pro-N3 4 11.7 98.5 2991.2 2990.8
10 HO-Lys-TCACTAGATG- Pro- triazole-(Lys)6-OH 8 11.08
b 98 3830.3 3832.5
b
11 Mixture of 4+8 when reaction was still incomplete. 11.6, 11.1
12 HO-(Arg-Aha-Arg)4-alkyne 9 12.9 100 1772.1 1772.38
13 HO-b-ala-tttttttt-pro-triazole-(Arg-Aha-Arg)4 -OH 10 17.2 89 4378.6 4376.29
14 HO-Lys-TCACTAGATG- Pro- triazole-(Arg-Aha-Arg)4-OH 11 12.7 95.4 4763.3 4763.8
15 50-alkyne-d(TTGTACTGATAGAGTGTCC)30 12 8.35 95 5878.04 5878.01
16 HO- (Arg-Aha-Arg)4- Pro-N3 13 13.8 95 1858.3 1881.2(+Na
+)
1897.2(+K
+)
17 HO- (Arg-Ahx-Arg)4- pro- triazole- 50-d(TTGTACTGATAGAGTGTCC) 30 14 11.04 81.6
c 7736.3 7735.09
atR-RP-HPLC retention time in minutes. T, C, G, A denote aegPNA units or DNA units and t denotes TANA unit, Pro-N3 denotes (2S,4S)-4-
azidoproline unit, alkyne denotes acetylene carboxylic acid, Aha denotes "-aminohexanoic acid.
bAlthough the HPLC retention time diﬀerence between the starting material and the product was small, the reaction was found to be essentially
complete as no corresponding peak for starting oligomer was observed in the mass spectrum of the product (Supplementary Data).
cHPLC after puriﬁcation shows a single peak without any starting materials.
(i) CuI, DIPEA, DMF
(ii) 10% TFA in DCM
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Scheme 2. Peptide–alkyne conjugation with 4-azidoproline using click
chemistry on solid support.
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Five milligrams of resin was cleaved by using the standard
conditions and the product formed was puriﬁed by HPLC
and characterized by MALDI-TOF mass spectrometry
(Table 1, entry 2).
Solutionphase reaction between PNA-proline azides 2,
3and4and HO-(Lys)6-alkyne 1:synthesis of
conjugates 6,7and 8
General procedure. HO-b-ala-TTTTTTTT-Pro-N3 2
(or HO-Lys-TCACTAGATG-Pro-N3 4 or HO-b-ala-t-t-
t-t-t-t-t-t-Pro-N3 3)( 1 mmol) and HO-(Lys)6-alkyne 1
( 3mmol) were dissolved in 50ml water:tert. butanol(1:1).
CuSO4.5H2O (1.0 equivalent, 1mmol, 10ml of a 100mM
solution in water) and freshly prepared solution of sodium
ascorbate (4 equivalents, 4mmol, 8ml of 500mM solution
in water) was then added. The mixture was stirred in
a spinix vortex at room temperature (Scheme 3). The
reaction mixture was analyzed by HPLC after 2h. HPLC
showed complete consumption of the starting material
in the case of 3 giving product 7 (Table 1, entry 7). In the
case of either 2 or 4 the diﬀerences in HPLC-tR was not
very clear from the starting materials. In these cases the
product (6 or 8) after HPLC puriﬁcation were character-
ized by MALDI-TOF mass spectrometry (Table 1, entry 4
and 10). Complete conversion of the starting material 2
and 4 was established by the disappearance of the
corresponding mass peak in MALDI-TOF analysis
(Supplementary Data).
Solid-phase synthesis ofthe peptide
HO-(Arg-Aha-Arg)4-alkyne 9
The arginine peptide 9 was synthesized on Rink-amide
resin (200mg, loading 0.3mmol/g) following the standard
procedures of solid-phase peptide synthesis: 20min treat-
ment with 20% piperidine in N,N-dimethyl formamide
and reaction with 3 equivalent of Fmoc-Arg(Mtr)-OH
(or N
e-Fmoc-Aha-OH), HBTU, HOBt and DIPEA for
4h, were used for the deprotection and coupling steps,
respectively. The ﬁnal coupling was done with propynoic
acid using HBTU, HOBt and DIPEA as the coupling
agent. Cleavage of the peptide from resin was eﬀected by
reaction with TFA/DCM/TIS (10:85:5) for 30min. The
deprotection of side-chain protecting group (Mtr) was
eﬀected by 100% TFA and thioanisole as the scavenger
for 5h. The resulting peptide was precipitated by addition
of cold ether and oligomer was puriﬁed by RP–HPLC.
The product was further characterized by MALDI-TOF
mass spectrometry (Table 1, entry 12).
Solution phasereaction between PNA-proline azides 3,
4and HO-(Arg-Aha-Arg)4-alkyne 9:synthesis
of conjugates 10 and11
General procedure. HO-Lys-TCACTAGATG-Pro-N3 4
or HO-b-ala-t-t-t-t-t-t-t-t-Pro-N3 3 (1mmol) and (Arg-
Aha-Arg)4-alkyne 9 ( 3mmol) were dissolved in 50ml
water:tert. Butanol (1:1). CuSO4.5H2O (1.0 equivalent,
1mmol, 10ml of a 100mM solution in water) and freshly
prepared solution of sodium ascorbate (4 equivalents,
4mmol, 8ml of 500mM solution in water) was then added
(Scheme 3). The mixture was stirred in a spinix vortex
at room temperature. The reaction mixture was analyzed
by RP–HPLC after 2h. HPLC showed complete conver-
sion of stating materials to the products. The products
(10 and 11) formed were puriﬁed by RP–HPLC and
characterized by MALDI-TOF mass spectrometry
(Table 1, entry 13 and 14).
Synthesis ofalkyne substituted DNA oligomer 12
The DNA sequence 12 was synthesized using commer-
cially available monomeric units using phoaphoramidite
chemistry on automated DNA synthesizer. The last
coupling was done using 50-O-(propynyl-N-3-benzoyl-
thymidin)-30-O-(N,N-diisopropylamino-O-cyanoethyl
-phosphoramidite) (Figure 2). (Supplementary Data).
The ON 12 was deprotected and cleaved from the solid
support. It was further puriﬁed by RP–HPLC and
characterized by MALDI-TOF mass spectrometry
(Table 1, entry 15).
Solid-phase synthesis of thepeptide
HO-(Arg-Aha-Arg)4-azide 13
The arginine peptide 13 was synthesized on Rink-amide
resin (200mg, loading 0.3mmol/g) following the standard
procedures of solid-phase peptide synthesis: 20min treat-
ment with 20% piperidine in N,N-dimethyl formamide
and reaction with 3 eqivalent of Fmoc-Arg(Mtr)-OH
(or N
e-Fmoc-Aha-OH), HBTU, HOBt and DIPEA
1 or 9
CuSO4, Sodium ascorbate
tert. butanol:water
Peptide NH
N
CO-PNA/TANA
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Scheme 3. Peptide–alkyne conjugation with 4-azidoprolyl ON using
click chemistry in solution.
(2S,4S)-4-azidoproline derivative propynoic acid 5′-O-propynyl-thymidin-3′-O-
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Figure 2. Alkyne and azide carrier units.
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respectively. The ﬁnal coupling was done with N-Boc-4-
azido-proline using HBTU, HOBt and DIPEA as the
coupling agent. Cleavage of the peptide from resin was
eﬀected by reaction with TFA/DCM/TIS (10:85:5) for
30min. The deprotection of side chain protecting group
(Mtr) was eﬀected by 100% TFA and thioanisole as the
scavenger for 5h. The resulting peptide was precipitated
by addition of cold ether and was puriﬁed by RP–HPLC.
The product was further characterized by MALDI-TOF
mass spectrometry (Table 1, entry 16).
Solution phasereaction between DNA-alkyne 12 and
HO-(Arg-Aha-Arg)4-azide 13:synthesis of conjugate14
Alkyne functionalized ON 12 (1mmol) and azide functio-
nalized peptide 13 ( 3mmol) were dissolved in 50ml
water:tert. Butanol (1:1). CuSO4.5H2O (0.6 equivalent,
0.6mmol, 6ml of a 100mM solution in water) and freshly
prepared solution of sodium ascorbate (2.4 equivalents,
4mmol, 6ml of 500mM solution in water) was then added
(Scheme 4). The mixture was stirred in a spinix vortex
at room temperature. After 1h, a small portion of the
reaction mixture was analyzed by RP–HPLC. HPLC
showed complete conversion of stating materials to
the product. The product 14 formed was puriﬁed by
RP–HPLC and characterized by MALDI-TOF mass
spectrometry (Table 1, entry 17).
RESULTS AND DISCUSSION
The aim of this study was to develop a simple and chemo-
speciﬁc method for the conjugation of peptides and ON
mimics such as PNA and TANA. The azide and acetylene
carrier units were chosen so that these could be installed
online during the solid supported peptide or PNA/TANA
synthesis at the N/C-terminus through an amide linkage
that is stable towards conditions employed for the depro-
tection and cleavage of the peptide/ON from the solid
support. The candidates chosen for this purpose were
propynoic acid and (2S,4S)- 4-azidoproline (Figure 2)
(41). DNA ON was functionalized at 50-end using
50-O-propynyl-thymidine-phosphoramidite (Figure 2),
(Supplementary Data). The 4-azidoproline was chosen in
this strategy, as it could also open up the possibility to
introduce the azide group at either C/N-terminus or in
the center of the PNA or peptide sequences as desired.
This could enable the conjugation of peptide at either
C- or N-terminus of PNA or peptide. To assess the
methodology and its application potential, we chose three
PNA sequences, a homopyrimidine PNA-T8, a mixed
purine-pyrimidine 10-mer PNA sequence and a recently
developed homothyminyl-oligomer with uncharged
thioacetamido nucleic acid (TANA) backbone (39). The
reaction medium was tert.-butanol:water that solubilizes
all the reactants and is also capable of scavenging hydroxy
radicals (44). The peptide sequence chosen was the lysine
(18) or the arginine rich peptide (19) that were known to
act as vehicle for PNAs to penetrate through the cell
membrane. The azide functionalized PNA oligomers 2
and 3 were synthesized on Rink-amide resin following
the standard procedures (42) of Fmoc based solid-phase
peptide synthesis. The last coupling reaction was done
using N-Boc-(2S,4S)-4-azidoproline monomer unit. The
azide functionalized mixed purine-pyrimidine PNA oligo-
mer 4 was synthesized following the standard procedures
of Boc-based solid-phase peptide synthesis (42). The
ﬁnal coupling reaction was done with N-Boc-(2S,4S)-
4-azidoproline. The alkyne functionalized lysine peptide 1
and arginine-rich peptide 9, were synthesized on Rink-
amide resin following the standard procedures of solid-
phase peptide synthesis. The ﬁnal coupling was done with
propynoic acid. To install the azide functional group on
DNA oligomer, we attempted to synthesize 50deoxy-
50-azido-thymidinyl-30-O-phosphoramidite, but this was
found to be quite unstable. We then synthesized 50-O-
propynyl-N3-benzoylthymidinyl-30-O-phosphoramidite
(Supplementary Data). The 50-end alkyne substituted
DNA sequence 12 was synthesized using automated
DNA synthesizer when the last coupling was with 50-O-
propynyl-N3-benzoylthymidinyl-30-O-phosphoramidite.
N-terminal azide containing arginine-rich peptide 13 was
synthesized as 9, and N-Boc-(2S,4S)-4-azidoproline was
used for the last coupling reaction. The installation of
reactive alkyne and azide functionalities on either the
peptide or ON, was followed by the experiments to study
the feasibility of the click cycloaddition reaction. The
peptide 1, attached to the solid support with all the
side chain lysine amino- and terminal carboxy- groups
protected, was treated with 3 equivalents of N-Boc(2S,4S)-
4-azidoproline in DMF in the presence of CuI. The
product 5 was isolated after cleavage from the support.
There was negligible diﬀerence in RP–HPLC tR but mass
showed conjugation of proline unit through the triazole
linkage (Scheme 2, Table 1, entry 5).
(Arg-Aha-Arg)4
HN
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N N
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5′-d(TTGT ACT GAT AGA GTG TCC)-3′
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5′-d(TTGT ACT GAT AGA GTG TCC)-3′ +
Scheme 4. DNA–alkyne conjugation with 4-azidoprolyl-peptide using click chemistry in solution.
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established, the solution phase reactions of PNAs with
N-terminal azidoproline (2 and 4) or TANA (3) and
N-terminal-alkyne substituted lysine peptide 1 and
arginine-rich peptide 9, were carried out in tert. butanol:
water medium in presence of CuSO4 and sodium
ascorbate as a catalyst (Scheme 3). The CuI catalyst was
found to be less eﬃcient as compared to CuSO4-sodium
ascorbate under these conditions. The reactions were
followed by HPLC. The reaction took longer time for
PNA, TANA substrates (16–32h) to completion with-
approximately one equivalent of each substrate. With
approximately three equivalents excess of 1 or 9 complete
conversion to the conjugated products (6–8 and 10, 11)
was observed within 2h. The DNA substrate 12 was
converted to the peptide–DNA conjugate 14 within
1h with 3 equivalents of the peptide (Scheme 4). Cu(I)
catalysis is known to degrade DNA due to the presence of
hydroxy radicals and addition of Cu(I) stabilizing ligands
such as polytriazoles is often recommended to circumvent
the DNA degradation (38). Arginine side chain imine
nitrogen is also known to eﬃciently stabilize Cu(I) (43).
It is therefore possible that the arginine peptide
used in this reaction could have contributed to the stabili-
zation of Cu(I) similar to the Cu(I)-binding ligands as
small percentage of DNA degradation was observed.
Additionally, presence of tert.-butanol as solvent in
this reaction would circumvent DNA degradation as
tert.-butanol is known scavenger of hydroxy radicals (44).
The yields of peptide–DNA conjugates may be further
improved by the use of Cu(I)-stabilizing ligands such as
polytriazoles (38) along with tert.-butanol as hydroxy
radical scavenger (44). The results are tabulated in Table 1
(entry 4, 7, 10, 13 and 14). The peptide–ON conjugates
with either the DNA (14), aegPNA backbone (6, 8 and 11)
or TANA backbone (7, 10) were obtained in high purity
using this simple cycloaddition reaction. The reaction
seems to be very speciﬁc without interfering with other
functional groups present, either on peptide or DNA/
PNA/TANA segments of the conjugates.
CONCLUSIONS
The peptide–DNA/PNA/TANA conjugation chemistry
presented in this paper will prove to be a unique solution
for CPP conjugation to antisense/siRNA therapeutics. In
this fast-developing ﬁeld, application is mainly restrained
by the problems faced in cellular delivery of modiﬁed
ONs. The ease of conjugation and compatibility of the
strategy with various substrates and functional groups
will prove to be an attractive alternative to present
methods for the synthesis of peptide–PNA conjugates.
It is sequence-independent with respect to either peptide
or PNA/DNA or other backbone modiﬁed DNA mimics
(such as TANA), which are being developed for antisense
applications. The reactive azide and alkyne groups can be
installed on either ON or peptide and the work presented,
has a potential for general application in nucleic acid–
peptide conjugation. This could be a method of choice
when a peptide of choice needs to be conjugated with
several ON sequences or diﬀerent modiﬁcations of
the same sequence for studying their bioactivity. Alter-
natively, the chosen ON may be conjugated with several
peptides to establish the biological eﬃcacy of diﬀerent
peptides. Some recent work was carried out to evaluate
the ON–peptide conjugates as a potential alternative
to the use of transfection agents to improve the eﬃcacy
of siRNA (45). It will be very interesting to study the
eﬀects of the chemistry of this new linkage on the
intracellular performance of the conjugates (9,19).
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